<DOC>
	<DOCNO>NCT00743431</DOCNO>
	<brief_summary>The purpose study evaluate safety tolerability Caelyx woman advance ovarian cancer , focus infusion reaction palmar-plantar erythrodysesthesia .</brief_summary>
	<brief_title>Caelyx Ovarian Cancer : Prevention Treatment Infusion Reactions Palmar-plantar Erythrodysesthesia ( Study P04085 ) ( COMPLETED )</brief_title>
	<detailed_description>This observational program aim gain tolerability safety data routine use Caelyx label indication ovarian cancer , focus infusion reaction PPE . Data raise premedication routinely used prevention side effect cause Caelyx . Premedications infusion reaction include corticosteroid , serotonin 3 ( 5HT3 ) antagonist , histamine 1 ( H1 ) blocker , histamine 2 ( H2 ) blocker . Premedications PPE include oral dexamethasone vitamin B6 . The management infusion reaction PPE record . A detailed record medical history may reveal patient group high risk experience side effect .</detailed_description>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Hand-Foot Syndrome</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<criteria>Women advance ovarian cancer : previous platin/taxane therapy document measureable and/or evaluable advanced metastatic cancer radiological image increase serum cancer antigen 125 ( CA 125 ) accord Rustin et al . Patients treat accord Austrian Summary Product Characteristics ( SPC )</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
</DOC>